Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag plus immunosuppressive therapy in newly diagnosed non-severe aplastic anemia
ChiCTR2600117565Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hetrombopag in aplastic anemia (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: 24-week Overall Hematological Response Rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2600117565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117565.